{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:06:54Z","timestamp":1789060014988,"version":"build-2803163510"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117004","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:52:56Z","timestamp":1787388776000},"page":"117004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Systemic therapies for gastroenteropancreatic neuroendocrine carcinomas: Current paradigm and future avenues"],"prefix":"10.1016","volume":"246","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3041-6340","authenticated-orcid":false,"given":"Charles W.","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2543-6946","authenticated-orcid":false,"given":"Aagamjit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atulya A.","family":"Khosla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8865-0299","authenticated-orcid":false,"given":"Rohit","family":"Thummalapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarbajit","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-2583","authenticated-orcid":false,"given":"Heloisa P.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrikha","family":"Chandrasekharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udhayvir S.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2026.117004_bib1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/ajcp\/aqaf013","article-title":"Histopathologic and genetic distinction of well-differentiated grade 3 neuroendocrine tumor versus poorly-differentiated neuroendocrine carcinoma in high-grade neuroendocrine neoplasms","volume":"163","author":"Sun","year":"2025","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"10.1016\/j.ejca.2026.117004_bib2","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3748\/wjg.v28.i10.1009","article-title":"An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms","volume":"28","author":"Fang","year":"2022","journal-title":"WJG"},{"issue":"1","key":"10.1016\/j.ejca.2026.117004_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ejca.2026.117004_bib4","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1038\/s41598-025-92974-x","article-title":"Development and validation of predictive models for distant metastasis and prognosis of gastroenteropancreatic neuroendocrine neoplasms","volume":"15","author":"Zhou","year":"2025","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.ejca.2026.117004_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.ejca.2026.117004_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.ejca.2026.117004_bib7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.ejca.2026.117004_bib8","unstructured":"Endocrine and Neuroendocrine Tumors. 5 ed: International Agency for Research on Cancer (IARC); 2025."},{"issue":"6","key":"10.1016\/j.ejca.2026.117004_bib9","first-page":"471","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.ejca.2026.117004_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/jne.70001","article-title":"Incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): an updated systematic review of population-based reports from 2010 to 2023","author":"Nordstrand","year":"2025","journal-title":"J Neuroendocrinol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117004_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.15798","article-title":"Epidemiology of Neuroendocrine Neoplasms in the US","volume":"8","author":"Dasari","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2026.117004_bib12","first-page":"1","article-title":"Understanding the increasing incidence of neuroendocrine tumors","author":"Pathak","year":"2023","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ejca.2026.117004_bib13","doi-asserted-by":"crossref","first-page":"30536","DOI":"10.1038\/s41598-024-81518-4","article-title":"Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms","volume":"14","author":"Uhlig","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ejca.2026.117004_bib14","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/cncr.31124","article-title":"Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases","volume":"124","author":"Dasari","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.117004_bib15","article-title":"Machine learning based predictive model and genetic mutation landscape for high-grade colorectal neuroendocrine carcinoma: a SEER database analysis with external validation","volume":"15","author":"Wu","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.117004_bib16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1186\/s12885-020-07581-y","article-title":"Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study","volume":"20","author":"Masui","year":"2020","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2026.117004_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13264","article-title":"Incidence and prevalence of neuroendocrine neoplasms in Norway 1993-2021","volume":"35","author":"Thiis-Evensen","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"7","key":"10.1016\/j.ejca.2026.117004_bib18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"7","key":"10.1016\/j.ejca.2026.117004_bib19","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1634\/theoncologist.2018-0382","article-title":"High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study","volume":"24","author":"Alese","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.117004_bib20","doi-asserted-by":"crossref","first-page":"40609","DOI":"10.1038\/srep40609","article-title":"Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers","volume":"7","author":"Freis","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ejca.2026.117004_bib21","first-page":"799","article-title":"The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade)","volume":"39","author":"Strosberg","year":"2010","journal-title":"Extrapulm. Neuroendocr. Carcinomas, Pancreas"},{"issue":"1","key":"10.1016\/j.ejca.2026.117004_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doaf008","article-title":"Association of treatment methods and survival in esophageal neuroendocrine carcinoma population of Surveillance, Epidemiology, and End Results database: a retrospective cohort study","volume":"38","author":"Yang","year":"2025","journal-title":"Dis. esophagus"},{"issue":"4","key":"10.1016\/j.ejca.2026.117004_bib23","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1245\/s10434-019-07203-3","article-title":"Survival in Patients with High-Grade Colorectal Neuroendocrine Carcinomas: The Role of Surgery and Chemotherapy","volume":"26","author":"Fields","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.117004_bib24","first-page":"299","article-title":"Survival according to primary tumor location, stage, and treatment patterns in locoregional gastroenteropancreatic high-grade neuroendocrine carcinomas","volume":"27","author":"Dasari","year":"2022","journal-title":"Oncol (Dayt Ohio)"},{"issue":"4","key":"10.1016\/j.ejca.2026.117004_bib25","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1245\/s10434-021-11016-8","article-title":"Prognosis for Poorly Differentiated, High-Grade Rectal Neuroendocrine Carcinomas","volume":"29","author":"Erstad","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117004_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.ejca.2026.117004_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12967","article-title":"Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms","volume":"33","author":"Pommergaard","year":"2021","journal-title":"J Neuroendocrinol"},{"issue":"11","key":"10.1016\/j.ejca.2026.117004_bib28","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1245\/s10434-022-12100-3","article-title":"Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?","volume":"29","author":"Borbon","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.117004_bib29","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1097\/SLA.0000000000003562","article-title":"Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas","volume":"274","author":"Mao","year":"2021","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejca.2026.117004_bib30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1245\/s10434-020-08730-0","article-title":"Impact of postoperative chemotherapy on the survival of patients with high-grade gastroenteropancreatic neuroendocrine carcinoma","volume":"28","author":"Schmitz","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.117004_bib31","first-page":"404","article-title":"Chemotherapy in Resected Neuroendocrine Carcinomas of the Digestive Tract: A National Study from the French Group of Endocrine Tumours","volume":"110","author":"Anne","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.ejca.2026.117004_bib32","doi-asserted-by":"crossref","first-page":"oyae372","DOI":"10.1093\/oncolo\/oyae372","article-title":"Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinoma","volume":"30","author":"Ho","year":"2025","journal-title":"The Oncologist"},{"key":"10.1016\/j.ejca.2026.117004_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920915299","article-title":"Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis","volume":"12","author":"McNamara","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.117004_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2026.117004_bib35","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2026.117004_bib36","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Heetfeld","year":"2015","journal-title":"Endocr.-Relat. Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2026.117004_bib37","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/jamaoncol.2022.3395","article-title":"Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial","volume":"8","author":"Morizane","year":"2022","journal-title":"JAMA Oncol"},{"issue":"S9","key":"10.1016\/j.ejca.2026.117004_bib38","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/cncr.32750","article-title":"Etoposide and cisplatin versus irinotecan and cisplatin as the first\u2010line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2026.117004_bib39","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10555-023-10121-2","article-title":"Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma","volume":"42","author":"Ooki","year":"2023","journal-title":"Cancer Metastas-- Rev"},{"key":"10.1016\/j.ejca.2026.117004_bib40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41416-025-03054-w","article-title":"Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study","volume":"133","author":"Sorbye","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.117004_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jnci\/djw277","article-title":"Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas","volume":"109","author":"Lamarca","year":"2017","journal-title":"JNCI : J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.ejca.2026.117004_bib42","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41416-024-02773-w","article-title":"Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms","volume":"131","author":"Elvebakken","year":"2024","journal-title":"Br J Cancer"},{"issue":"16","key":"10.1016\/j.ejca.2026.117004_bib43","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-16-3135","article-title":"Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study","volume":"23","author":"Hijioka","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.ejca.2026.117004_bib44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11864-021-00866-9","article-title":"Systemic treatment of gastroenteropancreatic neuroendocrine carcinoma","volume":"22","author":"Mollazadegan","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.117004_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13249","article-title":"European Neuroendocrine Tumor Society ENETS 2023 guidance paper for digestive neuroendocrine carcinoma","volume":"35","author":"Sorbye","year":"2023","journal-title":"J Neuroendocrinol."},{"issue":"16__suppl","key":"10.1016\/j.ejca.2026.117004_bib46","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1200\/JCO.2022.40.16_suppl.4020","article-title":"Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142","volume":"40","author":"Eads","year":"2022","journal-title":"JCO"},{"issue":"12","key":"10.1016\/j.ejca.2026.117004_bib47","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1038\/s41416-023-02462-0","article-title":"Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"129","author":"Morken","year":"2023","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2026.117004_bib48","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00280-015-2833-5","article-title":"Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration","volume":"76","author":"Chen","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3__suppl","key":"10.1016\/j.ejca.2026.117004_bib49","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.2024.42.3_suppl.589","article-title":"NABNEC: a randomised phase II study of nab -paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas (GI-NECs)","volume":"42","author":"Chantrill","year":"2024","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.ejca.2026.117004_bib50","article-title":"Efficacy and toxicity analysis of mFOLFIRINOX in high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Borghesani","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"4","key":"10.1016\/j.ejca.2026.117004_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/jne.70168","article-title":"Fawad H,et al. Efficacy of FOLFIRINOX in digestive neuroendocrine carcinoma","volume":"38","author":"Butt","year":"2026","journal-title":"J Neuroendocrinol"},{"issue":"7","key":"10.1016\/j.ejca.2026.117004_bib52","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.dld.2021.04.016","article-title":"FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin","volume":"53","author":"Hadoux","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.ejca.2026.117004_bib53","doi-asserted-by":"crossref","first-page":"921","DOI":"10.21037\/jgo-24-64","article-title":"Efficacy of first-line chemotherapy based on primary site of tumor versus etoposide-platinum in advanced gastroenteropancreatic neuroendocrine carcinoma","volume":"15","author":"Shen","year":"2024","journal-title":"J Gastrointest Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.117004_bib54","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-26-0017","article-title":"Grade progression and high-grade transformation in neuroendocrine neoplasms","volume":"33","author":"Grewal","year":"2026","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2026.117004_bib55","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2020.10.023","article-title":"An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping","volume":"183","author":"Kawasaki","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2026.117004_bib56","doi-asserted-by":"crossref","first-page":"102863","DOI":"10.1016\/j.ctrv.2024.102863","article-title":"Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: a literature review","volume":"132","author":"Tissera","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.117004_bib57","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.1368","article-title":"A long survival woman with primary small-cell carcinoma of the gallbladder: role of chemotherapy maintenance","author":"Elm\u2019hadi","year":"2017","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.ejca.2026.117004_bib58","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0102","article-title":"Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study","volume":"29","author":"Hadoux","year":"2022","journal-title":"Endocr-Relat Cancer"},{"issue":"32","key":"10.1016\/j.ejca.2026.117004_bib59","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline","volume":"41","author":"Del Rivero","year":"2023","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.ejca.2026.117004_bib60","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0231","article-title":"Management of high-grade neuroendocrine neoplasms: impact of functional imaging","volume":"32","author":"Islam","year":"2025","journal-title":"Endocr Relat Cancer"},{"issue":"15","key":"10.1016\/j.ejca.2026.117004_bib61","doi-asserted-by":"crossref","first-page":"25669","DOI":"10.18632\/oncotarget.12900","article-title":"Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2026.117004_bib62","doi-asserted-by":"crossref","first-page":"viii467","DOI":"10.1093\/annonc\/mdy293.001","volume":"29","author":"Yao","year":"2018","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2026.117004_bib63","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/cncr.32883","article-title":"Pembrolizumab for the treatment of programmed death\u2013ligand 1\u2013positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study","volume":"126","author":"Mehnert","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.117004_bib64","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41416-023-02298-8","article-title":"Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas","volume":"129","author":"Raj","year":"2023","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2026.117004_bib65","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1158\/1078-0432.CCR-19-4000","article-title":"Efficacy, safety, and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial","volume":"26","author":"Lu","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2026.117004_bib66","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.3390\/curroncol28060388","article-title":"Complete and durable response to nivolumab in recurrent poorly differentiated pancreatic neuroendocrine carcinoma with high tumor mutational burden","volume":"28","author":"Kang","year":"2021","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.117004_bib67","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/1078-0432.CCR-24-2461","article-title":"Activity and safety of avelumab in high-grade neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas progressive after chemotherapy (AveNEC Trial)","volume":"31","author":"Fottner","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2026.117004_bib68","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11864-024-01283-4","article-title":"Evolving immunotherapy strategies in gastrointestinal neuroendocrine neoplasms","volume":"26","author":"Urman","year":"2025","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117004_bib69","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1038\/s41467-023-38611-5","article-title":"Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin","volume":"14","author":"Capdevila","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.117004_bib70","doi-asserted-by":"crossref","first-page":"S1318","DOI":"10.1016\/j.annonc.2021.08.2119","article-title":"LBA41 Nivolumab (nivo) \u00b1 ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)","volume":"32","author":"Girard","year":"2021","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2026.117004_bib71","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/cncr.33591","article-title":"A phase II basket trial of Dual Anti\u2013CTLA\u20134 and Anti\u2013PD\u20131 Blockade in Rare Tumors (DART) SWOG S1609: high-grade neuroendocrine neoplasm cohort","volume":"127","author":"Patel","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.117004_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100364","article-title":"Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms","volume":"7","author":"Al-Toubah","year":"2022","journal-title":"ESMO Open"},{"issue":"17","key":"10.1016\/j.ejca.2026.117004_bib73","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1158\/1078-0432.CCR-20-0621","article-title":"Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers","volume":"26","author":"Klein","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2026.117004_bib74","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1038\/s41467-024-50969-8","article-title":"Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: the multicenter phase 2 NICE-NEC trial (GETNE-T1913)","volume":"15","author":"Riesco-Martinez","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.117004_bib75","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bcp.2018.04.009","article-title":"Chromogranin-A and its derived peptides and their pharmacological effects during intestinal inflammation","volume":"152","author":"Eissa","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ejca.2026.117004_bib76","article-title":"First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2026.117004_bib77","article-title":"SWOG S2012: Randomized phase II\/III trial of first line platinum (P)\/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC)","volume":"42","author":"Zhen","year":"2024","journal-title":"JCO"},{"issue":"23","key":"10.1016\/j.ejca.2026.117004_bib78","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.117004_bib79","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1038\/s41598-025-86237-y","article-title":"Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value","volume":"15","author":"Yin","year":"2025","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.ejca.2026.117004_bib80","first-page":"940","article-title":"DLL3 as an emerging target for the treatment of neuroendocrine neoplasms","volume":"27","author":"Yao","year":"2022","journal-title":"Oncol (Dayt Ohio)"},{"key":"10.1016\/j.ejca.2026.117004_bib81","doi-asserted-by":"crossref","first-page":"104524","DOI":"10.1016\/j.critrevonc.2024.104524","article-title":"DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review","volume":"204","author":"Peddio","year":"2024","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"9","key":"10.1016\/j.ejca.2026.117004_bib82","first-page":"1","article-title":"Delta-like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasms","volume":"9","author":"Thummalapalli","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2026.117004_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.3369","article-title":"2758MO Updated results from a phase I\/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers","volume":"36","author":"Beltran","year":"2025","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.ejca.2026.117004_bib84","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO-25-00363","article-title":"Phase I dose-escalation results for the delta-like ligand 3\/CD3 IgG-Like T-cell engager obrixtamig (BI 764532) in patients with delta-like ligand 3+ small cell lung cancer or neuroendocrine carcinomas","volume":"43","author":"Wermke","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2026.117004_bib85","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2025.43.16_suppl.3004","article-title":"Efficacy and safety of the DLL3\/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: results from an ongoing phase I trial","volume":"43","author":"Capdevila","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2026.117004_bib86","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.117004_bib87","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS3174","article-title":"Phase I study of [225Ac]Ac-ETN029, a DLL3-targeted radioligand therapy, in patients with advanced DLL3-expressing solid tumors","volume":"44","author":"Ferrario","year":"2026","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2026.117004_bib88","doi-asserted-by":"crossref","first-page":"CT189","DOI":"10.1158\/1538-7445.AM2026-CT189","article-title":"Abstract CT189: preliminary results from the phase 1b\/2, open-label, multi-center study of ZL-1310, a DLL3-targeted ADC, in patients with neuroendocrine carcinomas and other selected solid tumors","volume":"86","author":"Thummalapalli","year":"2026","journal-title":"Cancer res. (Chic. Ill)"},{"key":"10.1016\/j.ejca.2026.117004_bib89","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ejca.2026.117004_bib90","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41698-024-00739-y","article-title":"Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms","volume":"8","author":"Serrano","year":"2024","journal-title":"NPJ Precis Onc"},{"key":"10.1016\/j.ejca.2026.117004_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2026.103195","article-title":"Understanding extrapulmonary neuroendocrine carcinomas: survival, prognosis, and patient quality of life","volume":"149","author":"Raj","year":"2026","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.117004_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1695716","article-title":"CAR-T therapy for neuroendocrine neoplasms: a review of molecular targets and clinical translation","volume":"16","author":"Golounina","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.117004_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1592291","article-title":"Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer","volume":"16","author":"Ji","year":"2025","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.ejca.2026.117004_bib94","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J Thorac Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:10:04Z","timestamp":1789056604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":94,"alternative-id":["S0959804926007859"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapies for gastroenteropancreatic neuroendocrine carcinomas: Current paradigm and future avenues","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117004"}}